Morgan Stanley began buying shares of Catalyst Pharmaceuticals, which falls under the purview of SEC disclosure requirements.
1 report, 1 independent
Updated Jul 18
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Morgan Stanley began buying shares of Catalyst Pharmaceuticals, which falls under the purview of SEC disclosure requirements.
Who's involved
What this event is mainly aboutKeep exploring
The entities involved
-
Catalyst Pharmaceuticals
company in Coral Gables, United States
Nothing else this week.
-
SEC
Slovak company
-
Morgan Stanley
U.S. investment bank
Related events
- Shell disclosed its holdings to the SEC on September 8, 2026.
- Monolithic Power Systems filed disclosures with the SEC, listed on Nasdaq, and saw Royal Bank of Canada increase its stock stake.
- Nucor made disclosures with the SEC regarding its stock holdings and performance on July 3, 2026.
- ETF Portfolio Partners Inc. disclosed trading activity to the SEC on October 24, 2026.
- InnovAge Holding Corp. stock is traded on Nasdaq, and large shareholders must disclose transactions to the SEC.